For Immediate Release
Media Contact: Bob Cooper
Date: July 24, 2003
Claims Process Now Open for Idahoans Who Purchased Taxol
(Boise) - Idahoans who purchased Taxol or paclitaxel (including Onxol), drugs used in the treatment of cancer, may now file claims for reimbursement, Attorney General Lawrence Wasden said. The reimbursement is the result of a previously announced antitrust settlement between Bristol-Myers Squibb and the attorneys general of all 50 states, the U.S. territories and the District of Columbia.
Idaho consumers who purchased Taxol or its generic equivalent between January 1, 1999 and February 28, 2003 may be eligible to file a claim. The claim form and filing information is accessible via the Attorney General's website or by calling the Taxol Settlement Administrator toll free at: (800) 659–7609.
Claim forms must be postmarked by November 14, 2003.
The $62 million antitrust settlement resolved allegations that Bristol-Myers Squibb violated state and federal competition laws by blocking the entry of less expensive generic drugs into the marketplace. The settlement provides $12.5 million to consumers who were injured as a result of Bristol-Myers Squibb's actions.
"The delay of lower priced generic versions of the drug Taxol was an unlawful anti-competitive practice. The unlawful acts forced many Idahoans to pay more for chemotherapy," Attorney General Wasden said. "I strongly encourage Idahoans who purchased these drugs to apply for the reimbursement to which they are entitled."
Taxol and Onxol are used to treat breast and ovarian cancers in their late stages. The drugs are also sometimes used to treat lung cancer and certain cancers caused by AIDS, such as Kaposi's Sarcoma.
In addition to settling the states' claims, Bristol-Myers Squibb agreed to reimburse the state of Idaho $108,000 to settle the state's claims against the company.
- End -
NOTE TO READERS - This settlement information has expired and is no longer available.